Milestone Pharmaceuticals (MIST) Share-based Compensation (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Share-based Compensation came in at $1.3 million in Q1 2026, down 82.68% YoY from $7.4 million in Q1 2025, and down 63.91% on a QoQ basis from $3.6 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Share-based Compensation (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Share-based Compensation data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Share-based Compensation fell 82.68% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 4.15% YoY) and the FY2025 annual result came in at $7.5 million, up 29.17% from the prior year.
- Share-based Compensation slipped to $1.3 million in Q1 2026, from $3.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $18.6 million in Q3 2022 to a low of $1.3 million in Q1 2026.
- A 5-year average of $4.8 million and a median of $2.4 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 89.72% — and 2023, when it jumped 571.92%.
- Tracing MIST's Share-based Compensation over 5 years: stood at $2.1 million in 2022, then slipped by 12.41% to $1.9 million in 2023, then retreated by 21.47% to $1.5 million in 2024, then soared by 140.98% to $3.6 million in 2025, then tumbled by 63.91% to $1.3 million in 2026.
- The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), $3.6 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.00 Mn |
| Jun 30, 2026 | 7.00 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 3.55 Mn |
| Dec 31, 2025 | 3.55 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 7.40 Mn |
| Mar 31, 2025 | 7.40 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 7.20 Mn |
| Jun 30, 2024 | 7.20 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.51 Mn |